Published in Cardiovascular Device Liability Week, December 30th, 2007
"We hypothesized that vincristine, which disrupts microtubules, should have the opposite effect. To our surprise, we found that pretreatment with concentrations of vincristine ranging from 30 to 120 mu mol/L for 60 min preserved myocyte viability and morphology after incubation with 30 mu mol/L of H2O2 for 35 min as measured by trypan blue exclusion. The cardioprotective effects of vincristine were also...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Device Liability Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.